The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ASTER 70s: Benefit of adjuvant chemotherapy for estrogen receptor-positive HER2-negative breast cancer in women over 70 according to genomic grade—A French GERICO/UCBG UNICANCER multicenter phase III trial.
Etienne Brain
Consultant or Advisory Role - Cephalon
Honoraria - Cephalon
Research Funding - Amgen; Cephalon; Ipsogen
Veronique Girre
No relevant relationships to disclose
Florence Rollot
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Marc Debled
No relevant relationships to disclose
Magali Lacroix
No relevant relationships to disclose
Sandrine Baffert
No relevant relationships to disclose
Aurelien Latouche
No relevant relationships to disclose
Claire Falandry
No relevant relationships to disclose
Helene P. Peyro Saint Paul
Employment or Leadership Position - Ipsogen
Christine Orsini
No relevant relationships to disclose
Fabrice Andre
No relevant relationships to disclose
Herve R. Bonnefoi
No relevant relationships to disclose